The multinational pharmaceutical company Hikma Pharmaceuticals PLC (Hikma, Group) and Glenmark Specialty S.A., a subsidiary of
Glenmark Pharmaceuticals Ltd. has announced the launch of RYALTRIS (olopatadine hydrochloride and mometasone furoate nasal spray) in the US market.
The RYALTRIS drug is approved by the US Food and Drug Administration (FDA) for the treatment of symptoms of seasonal allergic rhinitis (SAR) in adult and pediatric patients of 12 years age and older.
As per the press release, this launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US.
RYALTRIS is the only fixed-dose combination therapy which helps to relief the symptoms of SAR, including both nasal and ocular in one easy-to-use nasal spray. The onset of action for nasal symptom relief occurs within 15 minutes of a patient taking the first dose.
“Nowadays, Allergic rhinitis and allergic conjunctivitis are among the most frequent chronic diseases in the US, affecting 60 million American citizens each year, yet approximately one in seven US adults have reported their nasal allergy symptoms are either poorly controlled or not controlled at all, and ocular symptoms are reported to be as severe as nasal symptoms,” said Leonard Bielory, M.D. Professor of Medicine, Allergy, Immunology and Ophthalmology at Hackensack Meridian School of Medicine.
“RYALTRIS provides new treatment option for patients suffering from this chronic condition affecting the nose and eyes as well.”
This seasonal allergic rhinitis is a serious condition that places a substantial burden on patients and society as whole. The symptoms of allergic rhinitis can lead to chronic complications including asthma, sinusitis, hearing impairment, and other allergy-related complications.
At around 10:30 AM, Glenmark Pharmaceuticals Ltd is currently trading at Rs372.75 per share up by Rs1.45 or 0.39% from its previous closing of Rs371.30 per share on the BSE.
For feedback and suggestions, write to us at editorial@iifl.com
IIFL Customer Care Number 
IIFL Capital Services Support WhatsApp Number
